Charlotte Nichols MP: speeches

4 Jul 2025–3 Jul 2026

How these years work

Our reporting years run from 4 July to 3 July, starting with the 2024 general election. They are not official parliamentary sessions. Office costs keep IPSA’s April–March financial years. Records may cover only part of a year; a missing record does not mean no work was done.

Read what this MP said, asked and contributed in Parliament.

3 published records · newest first.

Speeches

  • 5 Nov 2025 · Drug-related Deaths · Hansard source
    More

    I absolutely agree that more can be done without the need for a change in legislation, but it is concerning that the Home Office does not look at legislation. Despite everything that was said in the Home Affairs Committee’s inquiry on drugs in the last Parliament, for example, which made very clear how outdated our current legislative framework is, there does not seem to be curiosity about fixing this. I completely agree with what my hon. Friend said about treatment and testing, particularly at large-scale events and festivals, because that can be a lifesaving intervention. It is both bizarre and frustrating that the Home Office actively chooses not to take some of the measures it could take on safer drug consumption facilities and safer inhalation equipment. That is something that is very much within its gift. We cannot continue to hide behind a 1970s statue, periodically tightened but rarely reviewed, that has too often exacerbated harm. If the House wishes to take money out of criminal markets, I ask the Minister to work across Departments to expand diamorphine-assisted treatment, which is proven to be effective and cost-saving both here and abroad, to provide dignified, supervised care for those with the most entrenched opioid dependence. After all, it was in this country that that type of world-class treatment originated, with the publication of the Rolleston report in 1926. I have focused much of my remarks on opioids, but in the short time remaining I will touch on some other substances. The first substance is cocaine, with 1,279 deaths involving cocaine registered in 2024, which was 14.4% higher than in the previous year and 11 times higher than in 2011. That is perhaps not surprising, given that the UK is the largest consumer of cocaine per capita in Europe and the second-largest consumer of it in the world, according to the OECD. The National Crime Agency estimates that in 2023, England, Scotland and Wales consumed 117 tonnes of the drug. It is worth mentioning that around 52% of homicides are drug-related, and there is evidence that cocaine use is fuelling domestic violence. In 2023, a pilot scheme found that 59% of domestic abuse offenders arrested in seven police force areas tested positive for cocaine and/or opiates. The status quo is not working. The second substance is ketamine. While ketamine deaths are relatively low, with 60 deaths, the stats are again trending the wrong way, as is the prevalence of the drug in our communities. I refer Members to the rate of past-year ketamine use among 16 to 24-year-olds, which has doubled since the drug was reclassified from class C to class B in 2014. We need a fit-for-purpose national drug policy, not a platform for point scoring or performative “tough on crime” posturing while harms continue to mount. There is much talk at the moment about the reclassification of ketamine to a class A drug, as if that is some sort of panacea, despite the fact that deaths from heroin and cocaine—both class A substances—have been increasing year on year. It is as though the Home Office thinks that making something that is already illegal more illegal is somehow worthwhile. In the light of that, I have tabled a number of questions recently on the effectiveness of the reclassification. I am genuinely concerned that no analysis of that move has been made, and the intention is clearly to ramp it up further. Other policy levers are available. In particular, an emphasis should be placed on tackling the mental health crisis among our young people, which can make the dissociative effects of ketamine an appealing proposition. Throughout this debate, I have sought to lay out the extent of the problem and to offer realistic, cost-effective and constructive measures that could save this country billions of pounds, not to mention thousands of lives. There are solutions to these issues, and the UK has both the expertise and the capacity to lead in this area. We must simply find the political expediency and courage to take bold action and do what is right. We cannot govern as the careful custodians of a failed Conservative settlement; we must replace it. This is a solvable problem, and it is clear what works. With clear guidance, consistent commissioning and the courage to back frontline services, we can save lives, support families and ease pressure on our NHS. We will not solve this problem overnight, but I hope to come back next year with the figures at least trending in the right direction. No amount of warm words or hand-wringing in this place will absolve us of our collective responsibility if we do not take the steps necessary to do that now. We promised the country change, and it is now time to see it.

  • 5 Nov 2025 · Drug-related Deaths · Hansard source
    More

    My hon. Friend is exactly right: Change Grow Live is a fantastic organisation. Multi-year funding schemes with clear outcome metrics, such as faster time for treatment, improved retention and improved naloxone coverage, will make a difference in bringing down the figures I have talked about. That is the path out of this crisis. I recently received a letter from my hon. Friend the Minister for Policing and Crime stating she could not support overdose prevention centres because of concerns about organised crime supplying the drugs there. Overdose prevention centres are a frontline, evidence-based intervention that save lives and public money, reducing ambulance call-outs and A&E attendances, cutting public injecting and needlestick injuries, and creating a bridge into treatment. I recognise and share the Minister’s concerns about supply but, with or without such centres, people will use the same drugs, either in alleyways and stairwells or in safe hygienic settings where sharps are disposed of, and where staff can intervene and build relationships that can be the foundation for recovery from addiction. The Scottish Affairs Committee recently published a report into problem drug use in Scotland and Glasgow’s safer drug consumption facility, and it is interesting to note the call for legislative action from the UK Government and Parliament and the fact that they seem to share my frustration with the Home Office’s ideological rather than evidence-based approach on safer drug consumption facilities. In written correspondence to me, my hon. Friend the Minister for Policing and Crime also maintains that supplying essential safer inhalation equipment would contravene current legislation, and that the Government are unable to support such a provision or to provide a legal pathway to address this. Encouraging drug users to change their method of consuming drugs from injecting to inhaling can be an important harm reduction step, yet while supplying clean hypodermic needles is exempt under section 9A of the Misuse of Drugs Act 1971, the Government continue to support a policy of criminalisation of potential providers and users of safer inhalation equipment.

  • 5 Nov 2025 · Drug-related Deaths · Hansard source
    More

    I absolutely agree. Later, I will try to develop my argument for that kind of approach, which we could take here but do not. As a Parliament and as a society, we may have inadvertently come to accept the yearly statistics, and have perhaps not given them the necessary thought, but I stress that there are cost-effective solutions that could save the taxpayer money and save the lives of our constituents, while taking money out of the pockets of exploitative, organised criminal gangs. I am afraid to say that the problem may be far worse than is recognised. A recent report by King’s College London indicates that there has been a severe under-reporting of drug-related deaths over the past 15 years. The researchers found that drug-related deaths have been under-reported by 30%, and opioid-related deaths between 2011 and 2022 were found to be 55% higher than recorded, putting the estimated number of opioid-related deaths in that period north of 39,000.

Explore activity by topic or department

Contributions by debate topic

4 Jul 2025–3 Jul 2026. Existing keyword taxonomy applied to official debate titles and contributions; a contribution may appear in more than one topic and unclassified records are retained.

View as listCommunities and local government: 5Communities and local government5Culture, media and sport: 3Culture, media and sport3Democracy and constitution: 3Democracy and constitution3Economy and business: 4Economy and business4Education and skills: 1Education and skills1Environment and energy: 1Environment and energy1Health and care: 5Health and care5Immigration and borders: 2Immigration and borders2Justice and policing: 12Justice and policing12Transport: 4Transport4Unclassified: 6Unclassified6
What this shows and doesn't show
4 Jul 2025–3 Jul 2026. Existing keyword taxonomy applied to official debate titles and contributions; a contribution may appear in more than one topic and unclassified records are retained. Published records do not measure effort or effectiveness. Methodology.
Department or topicPublished records
Communities and local government5
Culture, media and sport3
Democracy and constitution3
Economy and business4
Education and skills1
Environment and energy1
Health and care5
Immigration and borders2
Justice and policing12
Transport4
Unclassified6

Published records only — not a full account of an MP’s work. How we work →